{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:33:34Z","timestamp":1783082014790,"version":"3.54.6"},"reference-count":20,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Individuals with Down syndrome are at increased risk of myeloid leukemia in early childhood, which is associated with acquisition of GATA1 mutations that generate a short GATA1 isoform called GATA1s. Germline GATA1s-generating mutations result in congenital anemia in males. We report on 2 unrelated families that harbor germline GATA1s-generating mutations in which several members developed acute megakaryoblastic leukemia in early childhood. All evaluable leukemias had acquired trisomy 21 or tetrasomy 21. The leukemia characteristics overlapped with those of myeloid leukemia associated with Down syndrome, including age of onset at younger than 4 years, unique immunophenotype, complex karyotype, gene expression patterns, and drug sensitivity. These findings demonstrate that the combination of trisomy 21 and GATA1s-generating mutations results in a unique myeloid leukemia independent of whether the GATA1 mutation or trisomy 21 is the primary or secondary event and suggest that there is a unique functional cooperation between GATA1s and trisomy 21 in leukemogenesis. The family histories also indicate that germline GATA1s-generating mutations should be included among those associated with familial predisposition for myelodysplastic syndrome and leukemia.<\/jats:p>","DOI":"10.1182\/blood.2021011463","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T20:05:23Z","timestamp":1636574723000},"page":"3159-3165","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["Germline GATA1s-generating mutations predispose to\u00a0leukemia with acquired trisomy 21 and Down syndrome-like phenotype"],"prefix":"10.1182","volume":"139","author":[{"given":"Henrik","family":"Hasle","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Kline","sequence":"additional","affiliation":[{"name":"2Healthcare and Insurance Program, United States Office of Personnel Management, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eigil","family":"Kjeldsen","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Aarhus University Hospital, Aarhus, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nik F.","family":"Nik-Abdul-Rashid","sequence":"additional","affiliation":[{"name":"4Hemostasis and Thrombosis Center of Nevada, Sickle Cell Center of Nevada, Las Vegas, NV;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Bhojwani","sequence":"additional","affiliation":[{"name":"5Division of Hematology-Oncology, Children\u2019s Hospital Los Angeles, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4454-6043","authenticated-orcid":false,"given":"Jeffrey M.","family":"Verboon","sequence":"additional","affiliation":[{"name":"6Division of Pediatric Hematology-Oncology, Boston Children\u2019s Hospital\/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"},{"name":"7Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie P.","family":"DiTroia","sequence":"additional","affiliation":[{"name":"7Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2897-2410","authenticated-orcid":false,"given":"Katherine R.","family":"Chao","sequence":"additional","affiliation":[{"name":"7Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4032-6617","authenticated-orcid":false,"given":"Klas","family":"Raaschou-Jensen","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Odense University Hospital, University of Southern Denmark, Odense, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefine","family":"Palle","sequence":"additional","affiliation":[{"name":"9Department of Woman\u2019s and Children\u2019s Health, Uppsala University, Uppsala, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michel","family":"Zwaan","sequence":"additional","affiliation":[{"name":"10Department of Pediatric Oncology, Erasmus Medical Center-Sophia Children\u2019s Hospital, Rotterdam, The Netherlands;"},{"name":"11Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0411-7594","authenticated-orcid":false,"given":"Charlotte Guldborg","family":"Nyvold","sequence":"additional","affiliation":[{"name":"12Hematology-Pathology Research Laboratory, Research Unit for Hematology and Pathology, Odense University Hospital, University of Southern Denmark, Odense, Denmark; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0044-443X","authenticated-orcid":false,"given":"Vijay G.","family":"Sankaran","sequence":"additional","affiliation":[{"name":"6Division of Pediatric Hematology-Oncology, Boston Children\u2019s Hospital\/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"},{"name":"7Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA;"},{"name":"13Harvard Stem Cell Institute, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan B.","family":"Cantor","sequence":"additional","affiliation":[{"name":"6Division of Pediatric Hematology-Oncology, Boston Children\u2019s Hospital\/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"},{"name":"13Harvard Stem Cell Institute, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2022052615231562900_B1","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/gim.2016.23","article-title":"Low risk of solid tumors in persons with Down syndrome","volume":"18","author":"Hasle","year":"2016","journal-title":"Genet Med."},{"issue":"7","key":"2022052615231562900_B2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/ng1825","article-title":"An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis","volume":"38","author":"Hollanda","year":"2006","journal-title":"Nat Genet."},{"issue":"7","key":"2022052615231562900_B3","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1172\/JCI63597","article-title":"Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia","volume":"122","author":"Sankaran","year":"2012","journal-title":"J Clin Invest."},{"issue":"6","key":"2022052615231562900_B4","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjh.12919","article-title":"Recurrent GATA1 mutations in Diamond-Blackfan anaemia","volume":"166","author":"Klar","year":"2014","journal-title":"Br J Haematol."},{"issue":"7330","key":"2022052615231562900_B5","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature09650","article-title":"Genetic variegation of clonal architecture and propagating cells in leukaemia","volume":"469","author":"Anderson","year":"2011","journal-title":"Nature."},{"issue":"7","key":"2022052615231562900_B6","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Engl J Med."},{"issue":"11","key":"2022052615231562900_B7","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1182\/blood-2003-01-0013","article-title":"GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome","volume":"101","author":"Hitzler","year":"2003","journal-title":"Blood."},{"issue":"6","key":"2022052615231562900_B8000","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ajhg.2018.10.027","article-title":"The Genetic Landscape of Diamond-Blackfan Anemia","volume":"103","author":"Ulirsch","year":"2018","journal-title":"Am J Hum Genet."},{"issue":"5","key":"2022052615231562900_B8","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/pbc.25871","article-title":"A child with dyserythropoietic anemia and megakaryocyte dysplasia due to a novel 5'UTR GATA1s splice mutation","volume":"63","author":"Zucker","year":"2016","journal-title":"Pediatr Blood Cancer."},{"issue":"7","key":"2022052615231562900_B9","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm.3557","article-title":"Altered translation of GATA1 in Diamond-Blackfan anemia","volume":"20","author":"Ludwig","year":"2014","journal-title":"Nat Med."},{"issue":"7","key":"2022052615231562900_B10","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/pbc.24944","article-title":"Loss of GATA-1 full length as a cause of Diamond-Blackfan anemia phenotype","volume":"61","author":"Parrella","year":"2014","journal-title":"Pediatr Blood Cancer."},{"issue":"2","key":"2022052615231562900_B11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2019.06.007","article-title":"Mechanisms of progression of myeloid preleukemia to transformed myeloid leukemia in children with Down syndrome","volume":"36","author":"Labuhn","year":"2019","journal-title":"Cancer Cell."},{"issue":"4","key":"2022052615231562900_B12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00431-014-2430-3","article-title":"Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children","volume":"174","author":"Ono","year":"2015","journal-title":"Eur J Pediatr."},{"issue":"4","key":"2022052615231562900_B13","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1365-2141.2004.05342.x","article-title":"GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder","volume":"128","author":"Carpenter","year":"2005","journal-title":"Br J Haematol."},{"issue":"6551","key":"2022052615231562900_B14","doi-asserted-by":"crossref","first-page":"eabf6202","DOI":"10.1126\/science.abf6202","article-title":"Mapping the cellular origin and early evolution of leukemia in Down syndrome","volume":"373","author":"Wagenblast","year":"2021","journal-title":"Science."},{"key":"2022052615231562900_B15","doi-asserted-by":"crossref","first-page":"636633","DOI":"10.3389\/fonc.2021.636633","article-title":"Molecular mechanisms of the genetic predisposition to acute megakaryoblastic leukemia in infants with Down syndrome","volume":"11","author":"Grimm","year":"2021","journal-title":"Front Oncol."},{"issue":"3","key":"2022052615231562900_B16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1055\/s-2005-836510","article-title":"Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts","volume":"217","author":"Langebrake","year":"2005","journal-title":"Klin Padiatr."},{"issue":"4","key":"2022052615231562900_B17","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/cytob.21198","article-title":"Acute megakaryoblastic leukemia associated with trisomy 21 demonstrates a distinct immunophenotype","volume":"88","author":"Wang","year":"2015","journal-title":"Cytometry B Clin Cytom."},{"issue":"13","key":"2022052615231562900_B18","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1182\/blood-2011-04-346643","article-title":"NUP98\/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern","volume":"118","author":"Hollink","year":"2011","journal-title":"Blood."},{"issue":"5","key":"2022052615231562900_B19","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.leu.2401753","article-title":"Cellular cytotoxic drug sensitivity in children with acute leukemia and Down\u2019s syndrome: an explanation to differences in clinical outcome?","volume":"14","author":"Frost","year":"2000","journal-title":"Leukemia."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/21\/3159\/1898564\/bloodbld2021011463.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/21\/3159\/1898564\/bloodbld2021011463.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T15:25:26Z","timestamp":1653578726000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/21\/3159\/477943\/Germline-GATA1s-generating-mutations-predispose-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":20,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2022,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021011463","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]}}}